Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Trichophyton for Intradermal Skin Testing

&times

Overview

What is Trichophyton for Intradermal Skin Testing?

Trichophyton

Trichophyton mentagrophytes

Trichophyton rubrum

WEIGHT BY VOLUME (W/V)



What does Trichophyton for Intradermal Skin Testing look like?



What are the available doses of Trichophyton for Intradermal Skin Testing?

Sorry No records found.

What should I talk to my health care provider before I take Trichophyton for Intradermal Skin Testing?

Sorry No records found

How should I use Trichophyton for Intradermal Skin Testing?

Intradermal skin tests with extract are indicated for use in persons who are suspected of having Type I hypersensitivity (i.e. allergy) to the fungus.

Prior to administering skin tests, the skin should be cleaned with alcohol and allowed to dry completely. The tests should be placed on the volar surface of the forearm and four rows may be placed on the back. The intradermal test is performed by administering 0.1 mL of extract into the skin. The injection should be given as superficially as possible creating a distinct bleb approximately 5 mm in diameter. The tests should be examined after 15 - 20 minutes and read as negative or positive. Test sites that show a wheal and flare response should be measured and reported in mm of edema and erythema or scored as 1+ to 4+ based on a mm reference scale. Induration after 24 - 48 hours can occur in some individuals and also may be recorded in mm.


What interacts with Trichophyton for Intradermal Skin Testing?

Conditions under which the administration of allergenic extract may be contraindicated, depending upon individual circumstances, include: EXTREME SENSITIVITY TO AN ALLERGEN - Determined from the allergic history, or from previous anaphylaxis following skin testing or subcutaneous injection; MYOCARDIAL INFARCTION - Patients who have experienced a recent myocardial infarction may be less able to tolerate the life-threatening effects of a serious adverse reaction. ASTHMA - Patients with highly unstable asthma are at greater risk of fatal reactions from skin tests than are patients without asthma, especially during seasonal exacerbations of the disease. Also, the combination of unstable asthma and treatment with B-adrenergic blockers appears to increase this risk. Allergenic extract should be temporarily withheld from patients if any of the following conditions exist: 1) severe symptoms of hay fever and/or asthma; 2) infection or flu accompanied by fever; and 3) exposure to excessive amounts of clinically relevant allergen(s) prior to skin testing.



What are the warnings of Trichophyton for Intradermal Skin Testing?

Patients who receive pamidronate disodium should have serum creatinine assessed prior to each treatment. Patients treated with pamidronate disodium for bone metastases should have the dose withheld if renal function has deteriorated (see


What are the precautions of Trichophyton for Intradermal Skin Testing?

GENERAL

PATIENT INFORMATION

DRUG INTERACTION

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

PREGNANCY CATEGORY C

NURSING MOTHERS

PEDIATRIC USE

Array

Array

Array

Array

Array

Array

Array

Array

Array

9

10

11

12

13


What are the side effects of Trichophyton for Intradermal Skin Testing?

LOCAL REACTIONS

SYSTEMIC REACTIONS

Array

Array

Array

Array

14


What should I look out for while using Trichophyton for Intradermal Skin Testing?

Conditions under which the administration of allergenic extract may be contraindicated, depending upon individual circumstances, include: EXTREME SENSITIVITY TO AN ALLERGEN - Determined from the allergic history, or from previous anaphylaxis following skin testing or subcutaneous injection; MYOCARDIAL INFARCTION - Patients who have experienced a recent myocardial infarction may be less able to tolerate the life-threatening effects of a serious adverse reaction. ASTHMA - Patients with highly unstable asthma are at greater risk of fatal reactions from skin tests than are patients without asthma, especially during seasonal exacerbations of the disease. Also, the combination of unstable asthma and treatment with B-adrenergic blockers appears to increase this risk. Allergenic extract should be temporarily withheld from patients if any of the following conditions exist: 1) severe symptoms of hay fever and/or asthma; 2) infection or flu accompanied by fever; and 3) exposure to excessive amounts of clinically relevant allergen(s) prior to skin testing.

Physicians who use allergenic extracts should have a knowledge and practical understanding of allergy skin testing as described in the published literature. Allergenic extracts are manufactured to assure high potency and therefore have the ability to cause serious local and systemic reactions, including death in highly sensitive patients. Patients should be informed of the risks of skin testing and instructed in the recognition of symptoms of an adverse allergic reaction (see PRECAUTIONS and ADVERSE REACTIONS below). Excessively large local reactions or systemic reactions are more likely to occur if the patient is skin tested shortly after exposure to allergens to which he or she is sensitive.


What might happen if I take too much Trichophyton for Intradermal Skin Testing?

The signs and symptoms of overdosage are the same as those listed under ADVERSE REACTIONS, paragraphs 1 and 2. The treatment of a systemic allergic reaction resulting from skin tests should include the following:

The above steps should be performed nearly simultaneously and as soon as possible after the reaction begins. Persistent wheezing may necessitate treatment with intravenous aminophylline and inhaled bronchodilators. For profound shock and hypotension, intravenous fluids, vasopressors and oxygen also may be needed. Maintenance of an open airway is critical if upper airway obstruction is present. Corticosteroids may provide benefit if symptoms are prolonged or recurrent.


How should I store and handle Trichophyton for Intradermal Skin Testing?

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP] .One mL of extract for intradermal skin testing is supplied in 2 mL sealed multidose vials. Each vial contains enough extract for 10 tests.


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

In sensitive persons, allergenic extract elicits immediate-type skin reactions consisting of erythema and edema at the test site. This allergic inflammatory response is thought to begin with the reaction of allergen with immunoglobulin E (IgE) on the surface of the mast cell. This antigen-antibody reaction initiates a series of biochemical events that result in the release of histamine and other mediators from the mast cell. These mediators are responsible for the characteristic wheal and flare response associated with a positive skin test. The initial antigen-antibody reaction appears to be a specific response that is dependent upon the presence of allergen-specific IgE attached to the mast cell. Delayed-type reactions occur in some individuals following the intradermal administration of extract. This response is due to the presence of sensitized lymphocytes. The reaction is characterized by erythema and induration that peaks between 24 and 48 hours after skin testing.

Non-Clinical Toxicology
Conditions under which the administration of allergenic extract may be contraindicated, depending upon individual circumstances, include: EXTREME SENSITIVITY TO AN ALLERGEN - Determined from the allergic history, or from previous anaphylaxis following skin testing or subcutaneous injection; MYOCARDIAL INFARCTION - Patients who have experienced a recent myocardial infarction may be less able to tolerate the life-threatening effects of a serious adverse reaction. ASTHMA - Patients with highly unstable asthma are at greater risk of fatal reactions from skin tests than are patients without asthma, especially during seasonal exacerbations of the disease. Also, the combination of unstable asthma and treatment with B-adrenergic blockers appears to increase this risk. Allergenic extract should be temporarily withheld from patients if any of the following conditions exist: 1) severe symptoms of hay fever and/or asthma; 2) infection or flu accompanied by fever; and 3) exposure to excessive amounts of clinically relevant allergen(s) prior to skin testing.

Physicians who use allergenic extracts should have a knowledge and practical understanding of allergy skin testing as described in the published literature. Allergenic extracts are manufactured to assure high potency and therefore have the ability to cause serious local and systemic reactions, including death in highly sensitive patients. Patients should be informed of the risks of skin testing and instructed in the recognition of symptoms of an adverse allergic reaction (see PRECAUTIONS and ADVERSE REACTIONS below). Excessively large local reactions or systemic reactions are more likely to occur if the patient is skin tested shortly after exposure to allergens to which he or she is sensitive.

Drugs can interfere with the performance of skin tests.

Antihistamines: Response to mediator (histamine) released by allergens is suppressed by antihistamines. The length of suppression varies and is dependent on individual patient, type of antihistamine and length of time the patient has been on antihistamines. The duration of this suppression may be as little as 24 hours (chlorpheniramine), and can be as long as 40 days (astemizole).

Tricyclic Antidepressants: These exert a potent and sustained decrease of skin reactivity to histamine which may last for a few weeks.

Beta Agonists: Oral terbutaline and parenteral ephedrine, in general, have been shown to decrease allergen induced wheal.

Dopamine: Intravenous infusion of dopamine may inhibit skin test responses.

Beta Blocking Agents: Propranolol can significantly increase skin test reactivity.

Other Drugs: Short acting steroids, inhaled beta agonists, theophylline and cromolyn do not seem to affect skin test response.

GENERAL

PATIENT INFORMATION

DRUG INTERACTION

CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY

PREGNANCY CATEGORY C

NURSING MOTHERS

PEDIATRIC USE

9

10

11

12

13

LOCAL REACTIONS

SYSTEMIC REACTIONS

14

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).